Limits...
Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

Kirschey S, Wagner S, Hess G - Clin Med Insights Oncol (2012)

Bottom Line: In consequence, prognosis of the disease has fortunately improved.We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL.At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Oncology, and Pneumology, University Medical School, Johannes Gutenberg-University, Langenbeckstr. 1, 55131 Mainz.

ABSTRACT
Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to guide at which place in the current treatment algorithms Temsirolimus can be integrated into the treatment of MCL patients.

No MeSH data available.


Related in: MedlinePlus

Schematic overview of potential treatment approaches – elderly/unfit patients.Abbreviations: R-CHOP, rituximab, cyclophosphamid, doxorubicin, vincristine, prednison; R-B, rituximab-bendamustine; FL, Firstline treatment; 2nd, second line treatment; >2nd, higher than second line treatments.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3306245&req=5

f2-cmo-6-2012-153: Schematic overview of potential treatment approaches – elderly/unfit patients.Abbreviations: R-CHOP, rituximab, cyclophosphamid, doxorubicin, vincristine, prednison; R-B, rituximab-bendamustine; FL, Firstline treatment; 2nd, second line treatment; >2nd, higher than second line treatments.

Mentions: Currently, different treatment approaches are in use: conventional chemoimmunotherapy, dose-escalated chemoimmunotherapy and palliative care, using single agents for frail patients. Potential algorithms for younger and elder patients are outlined in Figures 1 and 2. In brief, for the treatment of younger patients CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy has been the treatment of choice for a long period. While the use of single-agent Rituximab has shown a merely moderate activity in MCL with an overall response rate of only 27%,12 a number of studies have by now demonstrated a benefit in median progression free survival (median time from initiation of treatment and disease progression) and median OS when the drug is combined with chemotherapy,2,13–15 and combination therapies are nowadays considered standard of care.


Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

Kirschey S, Wagner S, Hess G - Clin Med Insights Oncol (2012)

Schematic overview of potential treatment approaches – elderly/unfit patients.Abbreviations: R-CHOP, rituximab, cyclophosphamid, doxorubicin, vincristine, prednison; R-B, rituximab-bendamustine; FL, Firstline treatment; 2nd, second line treatment; >2nd, higher than second line treatments.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3306245&req=5

f2-cmo-6-2012-153: Schematic overview of potential treatment approaches – elderly/unfit patients.Abbreviations: R-CHOP, rituximab, cyclophosphamid, doxorubicin, vincristine, prednison; R-B, rituximab-bendamustine; FL, Firstline treatment; 2nd, second line treatment; >2nd, higher than second line treatments.
Mentions: Currently, different treatment approaches are in use: conventional chemoimmunotherapy, dose-escalated chemoimmunotherapy and palliative care, using single agents for frail patients. Potential algorithms for younger and elder patients are outlined in Figures 1 and 2. In brief, for the treatment of younger patients CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy has been the treatment of choice for a long period. While the use of single-agent Rituximab has shown a merely moderate activity in MCL with an overall response rate of only 27%,12 a number of studies have by now demonstrated a benefit in median progression free survival (median time from initiation of treatment and disease progression) and median OS when the drug is combined with chemotherapy,2,13–15 and combination therapies are nowadays considered standard of care.

Bottom Line: In consequence, prognosis of the disease has fortunately improved.We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL.At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Oncology, and Pneumology, University Medical School, Johannes Gutenberg-University, Langenbeckstr. 1, 55131 Mainz.

ABSTRACT
Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to guide at which place in the current treatment algorithms Temsirolimus can be integrated into the treatment of MCL patients.

No MeSH data available.


Related in: MedlinePlus